The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study

ABSTRACT: Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) cohort study of the Canadian Consortium on Neurodegeneration in Aging (CCNA) is a national initiative to catalyze research on dementia, set up to support the research agendas of CCNA teams. This cross-country longitudinal cohort of 2310 deeply phenotyped subjects with various forms of dementia and mild memory loss or concerns, along with cognitively intact elderly subjects, will test hypotheses generated by these teams. Methods: The COMPASS-ND protocol, initial grant proposal for funding, fifth semi-annual CCNA Progress Report submitted to the Canadian Institutes of Health Research December 2017, and other documents supplemented by modifications made and lessons learned after implementation were used by the authors to create the description of the study provided here. Results: The CCNA COMPASS-ND cohort includes participants from across Canada with various cognitive conditions associated with or at risk of neurodegenerative diseases. They will undergo a wide range of experimental, clinical, imaging, and genetic investigation to specifically address the causes, diagnosis, treatment, and prevention of these conditions in the aging population. Data derived from clinical and cognitive assessments, biospecimens, brain imaging, genetics, and brain donations will be used to test hypotheses generated by CCNA research teams and other Canadian researchers. The study is the most comprehensive and ambitious Canadian study of dementia. Initial data posting occurred in 2018, with the full cohort to be accrued by 2020. Conclusion: Availability of data from the COMPASS-ND study will provide a major stimulus for dementia research in Canada in the coming years. RÉSUMÉ: Évaluation complète d’une étude de cohorte canadienne portant sur la démence et la neuro-dégénérescence. Contexte : L’évaluation globale de la neuro-dégénérescence et de la démence (COMPASS-ND), étude de cohorte du Consortium canadien en neuro-dégénérescence associée au vieillissement (CCNV), représente une initiative nationale visant à promouvoir la recherche portant sur la démence et à soutenir les programmes de recherche des équipes du CCNV. Totalisant 2310 sujets recrutés partout au pays, cette cohorte longitudinale regroupe des individus fortement « phénotypés » qui présentent diverses formes de démence et de pertes de mémoire légères. En plus de sujets âgés dont les fonctions cognitives sont intactes, ces 2310 sujets ont permis de valider les hypothèses formulées par les équipes du CCNV. Méthodes : Nous avons utilisé de nombreux documents pour décrire cette étude : le protocole de la COMPASS-ND ; la demande initiale de subvention ; le cinquième rapport d’étape semi-annuel du CCNV soumis aux Instituts de recherche en santé du Canada (IRSC) en décembre 2017 ; ainsi que d’autres documents produits à la suite de modifications consécutives à la mise en œuvre de ce projet. Résultats : L’étude de cohorte COMPASS-ND du CCNV inclut des participants de partout au Canada dont les divers états cognitifs sont associés à des maladies neurodégénératives ou au risque d’en souffrir. Ils feront l’objet d’un large éventail d’examens expérimentaux, cliniques, génétiques et d’imagerie afin d’aborder de manière spécifique les causes, le diagnostic, le traitement et la prévention de ces états cognitifs chez les personnes âgées. Les données obtenues à la suite d’évaluations cliniques et cognitives, ainsi que celles issues d’échantillons biologiques, d’imagerie cérébrale, de tests génétiques et de dons de cerveaux, seront utilisées pour tester les hypothèses générées par les équipes de recherche du CCNV et d’autres chercheurs canadiens. Cette étude constitue donc à ce jour l’étude canadienne la plus complète et la plus ambitieuse au sujet de la démence. La présentation des données initiales ayant eu lieu en 2018, la cohorte devrait atteindre sa taille maximale d’ici à 2020.Conclusion : La disponibilité des données de l’étude COMPASS-ND stimulera considérablement la recherche sur la démence au Canada au cours des prochaines années.

[1]  H. Chertkow,et al.  Development and validation of a salivary tau biomarker in Alzheimer's disease , 2019, Alzheimer's & dementia.

[2]  Eric E. Smith,et al.  New insights into cerebral small vessel disease and vascular cognitive impairment from MRI , 2017, Current opinion in neurology.

[3]  A. Evans,et al.  The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder , 2017, Current opinion in neurology.

[4]  D. Stuss,et al.  Small vessel disease is linked to disrupted structural network covariance in Alzheimer's disease , 2017, Alzheimer's & Dementia.

[5]  Douglas P. Munoz,et al.  Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI) , 2017, Journal of Alzheimer's disease : JAD.

[6]  Helen Tremlett,et al.  The gut microbiome in human neurological disease: A review , 2017, Annals of neurology.

[7]  Arthur W Toga,et al.  Global Data Sharing in Alzheimer Disease Research , 2016, Alzheimer disease and associated disorders.

[8]  Eric E. Smith,et al.  The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  H. Chertkow,et al.  Development and validation of a salivary tau biomarker in Alzheimer disease , 2015, Alzheimer's & Dementia.

[10]  Keith A. Johnson,et al.  Instrumental activities of daily living and functional connectivity in mild cognitive impairment , 2015, Alzheimer's & Dementia.

[11]  Michael W. Weiner,et al.  Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 , 2015, Alzheimer's & Dementia.

[12]  V. Quagliarello,et al.  The Microbiota and Microbiome in Aging: Potential Implications in Health and Age‐Related Diseases , 2015, Journal of the American Geriatrics Society.

[13]  Simon Duchesne,et al.  Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project , 2015, Alzheimer's & Dementia.

[14]  C. M. Sujatha,et al.  A Method to Differentiate Mild Cognitive Impairment and Alzheimer in MR Images using Eigen Value Descriptors , 2015, Journal of Medical Systems.

[15]  R. Knight,et al.  Gut Microbes and the Brain: Paradigm Shift in Neuroscience , 2014, The Journal of Neuroscience.

[16]  P. Sachdev,et al.  The role of epigenetics in cognitive ageing , 2014, International journal of geriatric psychiatry.

[17]  D. Stuss The Ontario Brain Institute: Completing the Circle , 2014, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[18]  H. Feldman,et al.  Early Neuropsychological Characteristics of Progranulin Mutation Carriers , 2014, Journal of the International Neuropsychological Society.

[19]  Aileen I. Pogue,et al.  Pathogenic microbes, the microbiome, and Alzheimer’s disease (AD) , 2014, Front. Aging Neurosci..

[20]  W. Lukiw,et al.  The Gastrointestinal Tract Microbiome and Potential Link to Alzheimer’s Disease , 2014, Front. Neurol..

[21]  L. Fratiglioni,et al.  Cognitive decline, dietary factors and gut–brain interactions , 2014, Mechanisms of Ageing and Development.

[22]  F. Jessen,et al.  AD dementia risk in late MCI, in early MCI, and in subjective memory impairment , 2014, Alzheimer's & Dementia.

[23]  Simon Duchesne,et al.  Detecting early preclinical Alzheimer's disease via cognition, neuropsychiatry, and neuroimaging: qualitative review and recommendations for testing. , 2014, Journal of Alzheimer's disease : JAD.

[24]  C. Iadecola,et al.  The Pathobiology of Vascular Dementia , 2013, Neuron.

[25]  W. Lukiw,et al.  Alzheimer's disease and the microbiome , 2013, Front. Cell. Neurosci..

[26]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[27]  V. Haroutunian,et al.  Epigenetic determinants of healthy and diseased brain aging and cognition. , 2013, JAMA neurology.

[28]  P. Sachdev,et al.  Factors Predicting Reversion from Mild Cognitive Impairment to Normal Cognitive Functioning: A Population-Based Study , 2013, PloS one.

[29]  R. Dixon,et al.  Neurocognitive Speed and Inconsistency in Parkinson's Disease with and without Incipient Dementia: An 18-Month Prospective Cohort Study , 2012, Journal of the International Neuropsychological Society.

[30]  M. Mintun,et al.  Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology , 2012, The journal of nutrition, health & aging.

[31]  Alan C. Evans,et al.  LORIS: a web-based data management system for multi-center studies , 2012, Front. Neuroinform..

[32]  Guanghua Xiao,et al.  A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.

[33]  R. Agarwal,et al.  Diagnostic Utility of CSF Tau and Aβ 42 in Dementia: A Meta-Analysis , 2011, International journal of Alzheimer's disease.

[34]  S. Black,et al.  Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[35]  Bruce L. Miller,et al.  Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia , 2011, Neuropsychologia.

[36]  A. Kertesz Frontotemporal dementia, Pick's disease. , 2004, Ideggyogyaszati szemle.

[37]  P. Raina,et al.  The Canadian Longitudinal Study on Aging (CLSA)* , 2009, Canadian Journal on Aging / La Revue canadienne du vieillissement.

[38]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[39]  B. Reisberg,et al.  Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease , 2008, International Psychogeriatrics.

[40]  R. Petersen,et al.  Mild Cognitive Impairment: An Overview , 2008, CNS Spectrums.

[41]  Margarita Kaushanskaya,et al.  The Language Experience and Proficiency Questionnaire (LEAP-Q): assessing language profiles in bilinguals and multilinguals. , 2007, Journal of speech, language, and hearing research : JSLHR.

[42]  D. Bennett,et al.  Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons , 2007, Annals of neurology.

[43]  PDt ShatensteinBryna,et al.  Development and Validation of a Food Frequency Questionnaire , 2007 .

[44]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.

[45]  J. Hardy,et al.  The genetics of neurodegenerative diseases , 2006, Journal of neurochemistry.

[46]  John C Morris,et al.  Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria. , 2006, Archives of neurology.

[47]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[48]  Julie S Snowden,et al.  Frontotemporal dementia , 2002, British Journal of Psychiatry.

[49]  R. Fitzpatrick,et al.  The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. , 1997, Age and ageing.

[50]  J. Cummings,et al.  The Neuropsychiatric Inventory , 1997, Neurology.

[51]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[52]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[53]  J. Morris The Clinical Dementia Rating (CDR) , 1993, Neurology.

[54]  F. Fazekas,et al.  Pathologic correlates of incidental MRI white matter signal hyperintensities , 1993, Neurology.

[55]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[56]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[57]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[58]  J Marshall,et al.  Cerebral blood flow in dementia. , 1975, Archives of neurology.

[59]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[60]  E. Ross,et al.  Philosophy of Science Association , 2022 .